ANI Pharmaceuticals (ANIP) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 172.2% versus a loss of 18.6%. Over five years, ETON leads with a +959.7% price change compared with +91.7% for ANIP. ANI Pharmaceuticals is the larger company by market cap ($1.70 billion vs $1.58 billion), about 1.1 times the size, while Eton Pharmaceuticals is growing revenue faster (+104.9% vs +43.8%).
On valuation, ANI Pharmaceuticals trades at a lower forward P/E (7.3x vs 21.4x for Eton Pharmaceuticals). ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -5.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | ETON |
|---|---|---|
| Share price | $73.89 | $55.21 |
| Market cap | $1.70B | $1.58B |
| 1-day change | +2.65% | +0.84% |
| YTD return | -6.40% | +226.49% |
| 1-year return | -18.61% | +172.24% |
| 5-year return | +91.72% | +959.69% |
| P/E ratio (TTM) | 15.99 | 138.03 |
| Forward P/E | 7.27 | 21.40 |
| EPS (TTM) | $4.62 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $883.37M | $79.95M |
| Revenue growth (YoY) | +43.78% | +104.94% |
| Net income (latest FY) | $78.34M | $-4.60M |
| Gross margin | 61.36% | 53.46% |
| Operating margin | 12.58% | -1.06% |
| Net margin | 8.87% | -5.75% |
| 52-week high | $97.00 | $66.37 |
| 52-week low | $69.58 | $14.27 |
| Distance from 52-week high | -23.82% | -16.81% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.16% | +28.60% |
| Average volume | 376.38K | 609.36K |
| Shares outstanding | 22.96M | 28.58M |
| Employees | 970 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed ANIP by 190.8 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (138.0x vs 16.0x trailing P/E).
- ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -5.8 cents for Eton Pharmaceuticals.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +43.78%).
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
ANIP vs ETON FAQ
Which is bigger, ANI Pharmaceuticals or Eton Pharmaceuticals?
ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.70B compared with $1.58B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ANIP or ETON?
ETON returned +172.24% over the past 12 months, compared with -18.61% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ANIP or ETON?
ANIP has the lower trailing P/E at 16.0, versus 138.0 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ANI Pharmaceuticals and Eton Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.